SCHEMBL4428247

SCHEMBL4428247

Cc1c(C)c(S(=O)(=O)NC(=N)NCCC[C@H](NC(=O)c2cccn(Cc3cccc(Cc4ccccc4)c3)c2=O)C(=O)O)c(C)c2c1OC(C)(C)CC2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLG P00747 3/20 0.40
PLAU P00749 2/20 0.40
F10 P00742 1/20 0.40
KLKB1 P03952 1/20 0.40
C3AR1 Q16581 1/20 0.34
BRD4 O60885 2/20 0.34
F2 P00734 2/20 0.34
BRD2 P25440 1/20 0.33
BRD3 Q15059 1/20 0.33
BRDT Q58F21 1/20 0.33
ST14 Q9Y5Y6 1/20 0.32
CNR1 P21554 3/20 0.32
CNR2 P34972 3/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MAPT P10636 2/20 0.31
TP53 P04637 1/20 0.31
HTT P42858 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4992945 0.96 PLG (0.38) PLGPLAUF10KLKB1C3AR1
SCHEMBL4995396 0.95 PLG (0.40) PLGPLAUF10KLKB1C3AR1
SCHEMBL4439721 0.95 PLG (0.40) PLGPLAUF10KLKB1C3AR1
SCHEMBL4994776 0.95 PLG (0.40) PLGPLAUF10KLKB1C3AR1
SCHEMBL4433268 0.93 PLG (0.40) PLGPLAUF10KLKB1C3AR1
SCHEMBL4986546 0.93 PLG (0.40) PLGPLAUF10KLKB1C3AR1
SCHEMBL4996655 0.93 PLG (0.40) PLGPLAUF10KLKB1C3AR1
SCHEMBL4438163 0.93 PLG (0.39) PLGPLAUF10KLKB1C3AR1
SCHEMBL4431655 0.93 PLG (0.40) PLGPLAUF10KLKB1C3AR1
SCHEMBL4997674 0.92 C3AR1 (0.39) PLGPLAUF10KLKB1C3AR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2125739-A1 MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. (US) 2009-12-02 EP disclosed
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof ENCYSIVE PHARMACEUTICALS, INC. 2008-08-07 US disclosed
WO-2008079371-A1 MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. (US) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof C3AR1, C5, C5AR1 PLG 52/4885PLAU 156/4885F10 432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.